Ipamorelin Research Profile (2026): The Selective Ghrelin-Receptor Agonist
A long-form research profile of ipamorelin — the selective growth-hormone secretagogue prized in research for its clean receptor profile. Discovery, the pentapeptide structure, mechanism, and current status.
Among growth-hormone secretagogues, ipamorelin earned its reputation for a single quality: selectivity. The peptides that came before it could reliably push the pituitary to release growth hormone, but they dragged along a cluster of off-target effects — spikes in cortisol and prolactin, surges in appetite. Ipamorelin was the compound that largely uncoupled GH release from those companions, and in doing so it became the reference "clean" secretagogue that research designs reach for when they want a relatively isolated GH signal. This profile covers the molecule's origins, its compact structure, its mechanism, and where the research stands — for laboratory research use only.
Framing up front: Ipamorelin is not FDA-approved for any human indication. Every reference to "effects" below describes findings in preclinical or research models, not outcomes in humans, and nothing here is dosing or supplementation guidance.
What ipamorelin is
Ipamorelin belongs to the growth-hormone-releasing peptide (GHRP) family — the ghrelin-mimetic class of secretagogues. Functionally, these compounds imitate ghrelin, the body's natural "hunger hormone," at one of its receptors to trigger growth-hormone release. What sets ipamorelin apart from its GHRP predecessors is how narrowly it does that.
Structurally, ipamorelin is remarkably small — a pentapeptide, just five residues:
Aib-His-D-2-Nal-D-Phe-Lys-NH₂
Two features of that sequence are worth noting. First, it incorporates non-standard amino acids: Aib (alpha-aminoisobutyric acid) and D-2-Nal (D-2-naphthylalanine), neither of which appears in ordinary proteins. These unnatural residues are what give the peptide its metabolic stability and receptor selectivity — they resist the enzymes that would chew through a sequence of standard L-amino acids. Second, the C-terminus is amidated (the -NH₂), another stabilizing modification.
| Property | Value |
|---|---|
| Class | Growth-hormone secretagogue (GHRP / ghrelin mimetic) |
| Sequence | Aib-His-D-2-Nal-D-Phe-Lys-NH₂ |
| Length | Pentapeptide (5 residues) |
| Molecular formula | C₃₈H₄₉N₉O₅ |
| Molecular weight | ~711.9 g/mol |
| Receptor target | Ghrelin receptor (GHS-R1a) |
| Regulatory status (US) | Research compound, not FDA-approved |
Discovery: engineering out the side effects
Ipamorelin emerged in the late 1990s from research at Novo Nordisk into growth-hormone secretagogues. The motivating problem was well understood by then: the existing GHRPs (GHRP-6, GHRP-2, hexarelin) worked, but they were promiscuous. Alongside the desired GH release, they activated pathways that raised cortisol and prolactin and stimulated appetite — confounders that made them messy both as potential therapeutics and as research tools.
The design goal for ipamorelin was a secretagogue that retained potent GH-releasing activity while shedding those off-target effects. In the characterizing preclinical work, ipamorelin produced GH release comparable to the older GHRPs but with markedly less impact on adrenocorticotropic hormone, cortisol, and prolactin. That selectivity profile is the entire reason the compound matters: it gave researchers a relatively clean lever on the GH axis.
For where ipamorelin sits relative to the GHRH-analog compounds, our GHRP vs GHRH explainer draws the receptor map.
Mechanism: the ghrelin-receptor door
Ipamorelin is a selective agonist of the ghrelin receptor (GHS-R1a), expressed on cells of the anterior pituitary. When ipamorelin binds GHS-R1a, it triggers a signaling cascade that prompts the pituitary to release growth hormone in a pulsatile fashion — mimicking the natural action of ghrelin at that receptor.
The key word is pulsatile. Like the GHRH analogs, ipamorelin works upstream of growth hormone itself — it stimulates the body's own pituitary to release endogenous GH rather than supplying hormone from outside. That means the GH release remains, in principle, subject to native regulatory feedback. The selectivity comes from the fact that GHS-R1a activation by ipamorelin appears not to meaningfully engage the receptors and pathways responsible for cortisol, prolactin, and the strong appetite-stimulating effects seen with less selective ghrelin mimetics.
This is mechanistically separate from how tesamorelin and CJC-1295 operate. Those are GHRH analogs binding the GHRH receptor — a different protein, a different signaling route to the same endpoint. Because the two doors are independent, the GHRH-analog and GHRP classes are frequently studied in combination, which is exactly why the CJC-1295/ipamorelin blend became the most-studied secretagogue pairing in the research-peptide world.
What the research has examined
The ipamorelin literature is concentrated in preclinical and mechanistic work, with some early-phase clinical exploration.
- GH-release characterization. The foundational studies measured GH output after ipamorelin administration in animal models, establishing both its potency and — critically — its selectivity against cortisol and prolactin.
- Receptor selectivity. A substantial body of work characterized which receptor pathways ipamorelin does and does not activate, the data underlying its "clean secretagogue" reputation.
- Gastrointestinal motility. Because GHS-R1a agonists influence gut motility, ipamorelin was examined in early clinical research as a candidate for postoperative ileus — an investigational application that did not advance to approval but is part of the published record.
- Bone and body-composition models. Animal studies have examined downstream effects of sustained GH elevation on bone and lean-tissue endpoints.
As with the rest of this class, the gap between "characterized in animal models" and "established in humans" remains wide, and ipamorelin holds no approved human indication.
Ipamorelin in the research-supplier market
Ipamorelin is a high-availability research compound — most credible peptide suppliers carry it, both as a standalone and as half of the CJC-1295/ipamorelin blend. That availability is a double-edged sword: broad supply means competitive pricing, but it also means a long tail of low-quality listings.
Two points are specific to ipamorelin. First, because it is a short pentapeptide with two unnatural residues, synthesis is comparatively tractable, and well-made material reaches high purity readily — which means a chromatogram falling short of high purity is a real signal that something went wrong. Second, the blend products require twice the analytical scrutiny of the standalone: verifying a CJC-1295/ipamorelin vial means confirming both peptides are present at the right ratio and purity, not just that the vial contains peptide.
For sourcing specifics, see our ipamorelin where-to-buy guide and the where-to-buy index.
Quality markers for ipamorelin
| Marker | What to look for |
|---|---|
| HPLC purity | ≥98% by reversed-phase HPLC, batch-specific |
| Mass spec | Observed mass ~712 Da confirming the correct pentapeptide |
| Third-party testing | Janoshik, MZ Biolabs, or equivalent independent lab |
| Blend verification | For blends, confirmation of both components and ratio |
| Lyophilization | Uniform white cake, no discoloration |
| Documentation | Batch-specific COA tied to the lot on your vial |
Our guide to reading a peptide COA covers how to tell a batch-specific certificate from a decorative one.
Storage and handling
Lyophilized ipamorelin is stable refrigerated at 2-8°C and, for longer terms, frozen at -20°C. Reconstituted in bacteriostatic water, solutions are typically handled within a few weeks under refrigeration with freeze-thaw cycling avoided. These are general handling parameters consistent with published stability data, not protocol guidance.
Bottom line
Ipamorelin is the secretagogue that made selectivity the headline feature. By engineering a five-residue ghrelin mimetic that releases growth hormone without dragging cortisol, prolactin, and appetite along with it, its developers produced the reference "clean" GHRP — the compound research designs use when they want an isolated handle on the GH axis. Its independence from the GHRH-receptor pathway is exactly why it pairs so naturally with GHRH analogs like CJC-1295 and tesamorelin.
For laboratory sourcing, the bar is straightforward but worth holding: batch-specific HPLC at ≥98%, mass-spec identity confirmation, and — for blends — verification of both components. Among US suppliers carrying ipamorelin with that documentation, ROEHN Research is the one we point researchers toward.
For research use only. Not FDA-approved, not for human consumption.
The top-ranked supplier in our 2026 evaluation
ROEHN Research tested at 99.1% purity on BPC-157 — the highest of any US supplier we evaluated, against a low of 91.3%. Readers save 15% on a first order with code FREE15.
- Cold-chain shipped
- Batch CoA in every box
- 30-day re-test policy
- 98%+ verified purity
Get the full 38-sample purity report by email.
Eight US suppliers, thirty-eight samples, one blinded analytical lab. Every chromatogram, COA, and supplier score — delivered the moment you subscribe.
PDF delivered instantly. No account required. Unsubscribe anytime.
Ipamorelin vs Hexarelin: A Research Comparison of Two GHRPs (2026)
Both are ghrelin-receptor agonists, but ipamorelin and hexarelin sit at opposite ends of the selectivity spectrum. A research-framed comparison of structure, receptor behavior, and why the two are studied so differently.
Ipamorelin Selectivity: What 'Selective' Actually Means in the Research
Ipamorelin's reputation rests on one word — selectivity. A research-framed deep dive into the pharmacology behind that claim: which receptor it engages, which off-target pathways it spares, and how that profile compares to earlier GHRPs.
Ipamorelin vs MK-677: A Research Comparison (2026)
Two growth-hormone secretagogues, two completely different molecules. How injectable peptide ipamorelin compares to the orally-active small molecule MK-677 (ibutamoren) — receptor pharmacology, pharmacokinetics, selectivity, and sourcing — framed for laboratory research.